Dynamic Advisor Solutions LLC Has $1.48 Million Stake in Danaher Co. (NYSE:DHR)

Dynamic Advisor Solutions LLC lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 12.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,462 shares of the conglomerate’s stock after selling 913 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Danaher were worth $1,483,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Eclectic Associates Inc. ADV increased its stake in shares of Danaher by 8.7% during the 4th quarter. Eclectic Associates Inc. ADV now owns 964 shares of the conglomerate’s stock worth $221,000 after purchasing an additional 77 shares during the last quarter. CX Institutional boosted its holdings in Danaher by 2.1% in the fourth quarter. CX Institutional now owns 2,970 shares of the conglomerate’s stock worth $682,000 after purchasing an additional 62 shares in the last quarter. Manitou Investment Management Ltd. increased its position in Danaher by 0.5% during the fourth quarter. Manitou Investment Management Ltd. now owns 92,685 shares of the conglomerate’s stock worth $21,276,000 after buying an additional 481 shares during the last quarter. Hengehold Capital Management LLC raised its holdings in Danaher by 30.3% during the fourth quarter. Hengehold Capital Management LLC now owns 2,340 shares of the conglomerate’s stock valued at $537,000 after buying an additional 544 shares in the last quarter. Finally, True North Advisors LLC lifted its position in shares of Danaher by 70.8% in the fourth quarter. True North Advisors LLC now owns 1,720 shares of the conglomerate’s stock worth $395,000 after buying an additional 713 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

NYSE:DHR opened at $245.95 on Friday. The company has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company has a 50-day moving average of $235.33 and a 200-day moving average of $253.45. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DHR shares. Scotiabank began coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective on the stock. UBS Group dropped their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Citigroup decreased their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a report on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.